

"Cannabis is the single most versatile herbal remedy, and most useful plant on earth. No other single plant contains as wide a range of medically active herbal constituents."



Dr. Ethan Russo  
Cannabinoid Research Institute

# DISCLAIMER

- THIS PRESENTATION IS CONFIDENTIAL AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM ANY JURISDICTION WHERE SUCH DISTRIBUTION IS UNLAWFUL.
- This presentation ("Presentation") is being provided to you by Kanabo Group PLC ("Kanabo" or the "Company") for information purposes only and does not constitute or form part of, and should not be construed as, an offer or invitation to sell or any solicitation of any offer to purchase or subscribe for any securities of the Company. The content of this Presentation has not been approved by an authorised person for the purposes of Section 21(2)(b) of the Financial Services and Markets Act 2000. Reliance on this Presentation for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested.
- This Presentation is not a prospectus or an admission document or an advertisement and should not be relied upon or treated as such. This Presentation is for the confidential use of only those persons to whom it is distributed and is not to be reproduced, distributed or used for any other purposes. No advice has been sought on any legal or taxation matter relating to the information set out in this Presentation and nothing in this Presentation constitutes investment, tax, legal or other advice. Recipients should seek their own legal, tax and financial advice in connection with the information contained herein.
- By receiving this Presentation, each recipient agrees to treat this Presentation as strictly confidential and not to reproduce, distribute or otherwise use this Presentation or any of its contents without the prior written consent of Kanabo.
- An investment in Kanabo, whether present or future, will place investor capital at risk and an investor may not get back the full amount invested. Neither past performance nor any forward-looking statements should be considered a reliable indicator of future results.
- This Presentation has been prepared for investment professionals for information and discussion purposes only and has not been approved for any other purpose. If you forward this Presentation to any other person, you must ensure that you have taken responsibility for it under applicable financial promotion rules. The information contained herein is in summary form, subject to change, and has been set out for illustrative purposes only and no reliance should be placed for any purpose on the information or opinions contained in this Presentation or their accuracy or completeness.
- The Presentation contains information and analysis that is believed to be accurate at the time of publication, but is subject to change without notice. The Presentation contains information of a preliminary nature that is based on unaudited information. Any proposals contained herein are subject to internal approvals, due diligence and documentation. This Presentation contains unaudited information and information from third party sources. Whilst care has been taken in compiling the content of this Presentation, the information and opinions contained in this Presentation are for background purposes only and do not purport to be full or complete. No reliance may be placed for any purpose on the information or opinions contained in this Presentation. This Presentation is not intended to provide the basis for any decision in respect of the Company whatsoever. Nothing in this Presentation forms the basis of or may be relied on in connection with or act as an inducement to enter into any contract or commitment whatsoever. No representation or warranty, express or implied, is made by Kanabo as to its accuracy or completeness, including for external sources (which may have been used) which have not been verified. This Presentation should not be copied, reproduced, divulged or distributed, in whole or in part, without the express written consent of Kanabo.
- All information contained herein is subject to updating, revision and/ or amendment (although there shall be no obligation to do so). Whilst the Company reasonably believes that the facts stated in this Presentation are accurate and that any forecasts, opinions and expectations contained therein are fair and reasonable, no representation or warranty, express or implied, is made to the fairness, accuracy, completeness or correctness of these materials or opinions contained therein and each recipient of this presentation must make its own investigation and assessment of the matters contained therein. In particular, but without prejudice to the generality of the foregoing, no representation or warranty is given, and no responsibility or liability is accepted, as to the achievement or reasonableness of any future projections or the assumptions underlying them, or any forecasts, estimates, or statements as to prospects contained or referred to in this presentation.
- This Presentation contains certain forward-looking statements. In some cases forward looking statements can be identified by the use of terms such as "believes", "estimates", "anticipates", "projects", "expects", "intends", "may", "will", "seeks", or "should" or variations thereof, or by discussions of strategy, plans, objectives goals, future events or intentions. By their nature, forward-looking statements involve risk and uncertainty because they relate to future events and circumstances. Actual outcomes and results may differ materially from any outcomes or results expressed or implied by such forward-looking statements.
- All statements of opinion or belief contained in this Presentation and any forward-looking statements represent Kanabo's own assessment and interpretation of information available to it as at the date of this presentation. No representation is made, or assurances are given that such statements or views are correct or that the objectives of Kanabo will be achieved. Prospective investors must determine for themselves what reliance (if any) they should place on such statements, views or forecasts, and no responsibility is accepted by Kanabo in respect thereof.
- No representation is made, assurance is given, or reliance may be placed, in any respect, that such information is correct and no responsibility is accepted by Kanabo or any of its officers, agents or advisers as to the accuracy, sufficiency or completeness of any of the information or opinions, or for any errors, omissions or misstatements, negligent or otherwise, contained in or excluded from this Presentation or for any direct, indirect or consequential loss or damage suffered or incurred by any person in connection with the information contained herein save to the extent that such liability arises out of fraud or fraudulent misrepresentation.
- Nothing contained herein constitutes either an offer to sell, or the solicitation of an offer to acquire or subscribe for, shares or other securities or to enter into any agreement or arrangement in relation to matters discussed in this Presentation. Nothing herein should be taken as a financial opinion or recommendation on the part of Kanabo to enter into any transaction.
- This Presentation is not for release, publication or distribution, directly or indirectly, in whole or in part in any jurisdiction where such release, publication or distribution would be unlawful or would impose any unfulfilled registration, qualification, publication or approval requirements on Kanabo. Persons into whose possession this Presentation comes must inform themselves about, and observe, any such restrictions as any failure to comply with such restrictions may constitute a violation of the securities law of any such jurisdiction.



# DISCLAIMER

- This Presentation has not been approved for the purposes of section 21 of the Financial Services and Markets Act 2000 (“FSMA”). This Presentation is being issued to and directed only at: (i) overseas persons within the meaning of Article 12 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Financial Promotion Order”); or (ii) any other persons to whom this Presentation for the purposes of Section 21 of FSMA can otherwise lawfully be made without further action; or (iii) persons otherwise permitted by the laws of the jurisdiction in which they are resident to receive it;. This Presentation is not intended to be, and must not be, distributed, passed on or disclosed, directly or indirectly, to any other class of person. This Presentation is only directed at persons outside the United Kingdom, and must not be acted upon by any persons in the United Kingdom. It is a condition of you viewing this Presentation that you fall within one of the categories of persons described above and by viewing this Presentation you will be taken to have warranted, represented and undertaken to Kanabo that: (a) you fall within one of the categories of persons described above, (b) you have read, agree to and will comply with the terms of this disclaimer; and (c) you will conduct your own analyses or other verification of the data set out in this Presentation and will bear the responsibility for all or any costs incurred in doing so. Persons who do not fall within one of the categories of persons described above should not view nor rely on this Presentation nor take any action upon it, but should immediately cease viewing of this Presentation.
- If there is any aspect of this Presentation that you do not understand, you should see advice from an appropriately authorised financial adviser.
- You are reminded that you have received this Presentation on the basis that you are a person into whose possession it may be lawfully delivered in accordance with the laws of the jurisdiction in which you are located and you may not nor are you authorised to deliver this Presentation, electronically or otherwise, to any other person. This Presentation has been made available to you in an electronic form. You are reminded that materials transmitted via this medium may be altered or changed during the process of electronic transmission and consequently neither the Company nor any of its respective affiliates accepts any liability or responsibility whatsoever in respect of any difference between the Presentation distributed to you in electronic format and the original version. By accessing the Presentation, you consent to receiving it in electronic form.
- No responsibility or liability whatsoever is accepted by any person for any loss howsoever arising from any use of, or in connection with, this document or their contents or otherwise arising in connection therewith. In making this Presentation, Kanabo undertakes no obligation to update or to correct any inaccuracies which may become apparent in this Presentation.

KANABO<sup>+</sup>

Nature made precise.



\* Subject to completion- GP & Materia deals are at heads of terms stage

# Board & Management

Experience across Cannabis, Pharmaceuticals, and Entrepreneurship with proven track record of generating significant shareholder returns

## Board

---



**David Tzur**  
Non-Executive  
Chairman



**Uzi Danino**  
Non-Executive Director



**Andy Morrison**  
Non-Executive Director



**Dr. Daniel Poulter**  
Non-Executive Director

## Management

---



**Avihu Tamir.**  
CEO, Kanabo



**Atul Devani**  
CEO – The GP Service



**Meirav Horn, CPA**  
CFO, Kanabo



**Suleman Sacranie**  
CPO – The GP Service



**Michal Ben Moshe**  
General Manager, Kanabo


\* Proposed management subjected to M&N completion

**KANABO<sup>+</sup>**



# Our Mission

Re-imagining medical cannabis delivery  
with a **patient-centric focus**



\* Subject to completion- GP & Materia deals are at heads of terms stage

KANABO<sup>+</sup>

# Focusing on the Patient

## The Cannabis Industry Evolution



2014 – 2019  
Cultivation era

Margin today  
**20–40%**



2019 – 2022  
Production era

Margin today  
**40–70%**



2022 +  
Patient-focused era

Anticipated margin  
**70%+**





**London**  
Stock Exchange



# 2021: A breakthrough year for Kanabo

One of the first Cannabis IPOs on the Main Market  
London Stock Exchange **February 16<sup>th</sup>, 2021**

Medical Cannabis – UK Distribution agreement  
with LYPHE Group **February 23<sup>rd</sup>, 2021**

Medical Cannabis – EU Production line  
JV with PharmaCann **March 9<sup>th</sup>, 2021**

Dr Daniel Poulter MP joins as a NED  
former UK Government health minister **July 1<sup>st</sup>, 2021**

UK Medical Launch – First Medical Cannabis vape in the UK  
with LYPHE Group **August 2021**

CBD Wellness Launch – new vape formats in the UK and EU  
with Handpicked CBD **September 2021**


Clinical trial starts – The first of its kind  
with Hadasa Hospital, Israel **October 2021**

**KANABO<sup>+</sup>**



# We are not seed-to-sale, but rather product-to-patient.


To facilitate scale and minimize risk, we intend to build a value chain that make sense for the cannabis sector.



- Israeli R&D Centre
- IP Medical device and formulations
- Gen 1 Vape Pod
- Gen 2 New device

# We are not seed-to-sale, but rather product-to-patient.

To facilitate scale and minimize risk, we intend to build a value chain that make sense for the cannabis sector






# Addressing the biggest challenges of the cannabis market



## DELIVERY



Limited Delivery  
Method Options

## PATIENTS



Insufficient Access for  
Patients

# Addressing the biggest challenges of the cannabis market



## DELIVERY



Limited Delivery  
Method Options


## PATIENTS



Insufficient Access for  
Patients



# No existing delivery methods address both stakeholder requirements



The Problem:

It's 2021, and most  
medical patients still  
smoke their medicine

Inconsistent

Risky

Immeasurable

Delivery Method



70-80%\*

Of Medical sales are flowers

\* Based on German, Israeli and UK markets





## The Solution:

# The first of its kind metered-dose, medical device vaporizer



Precise Dosage  
(1mg / inhalation)



Medical Device  
(CE Mark)\*



High  
Bioavailability

jupiter 

Jupiter Research  
(developer)

+\$100M in Sales

SMOORE

Smoore Technologies  
(manufacturer)

\$30B in Valuation

KANABO<sup>+</sup>

Kanabo Group  
(distributor)

\*In progress

KANABO<sup>+</sup>

Delivery Method



# Kanabo's unique platform offers formulations for three medical indications



Sleep Disorder  
Nabinno<sup>TM</sup>



Pain  
Management



PTSD

European Medical Cannabis Market (2025)

€3.2Bn

Delivery Method

KANABO<sup>+</sup>

# Leveraging Kanabo's recognized medical brand as a premium CBD wellness line



European CBD Market (2025)

€13.6Bn

Delivery Method

UK GMP  
production line  
established



- Premium quality backed by R&D
- Superior hemp-based CBD & terpene formulas
- Broad spectrum hemp extract retaining the naturally occurring components of the plant - cannabinoids and terpenes.

# Addressing the biggest challenges of the cannabis market



## DELIVERY



Limited Delivery  
Method Options

## PATIENTS



Insufficient Access for  
Patients



# Building a strong presence in the UK's medical and wellness markets – the challenge:



## No NHS prescription

Medical Cannabis is **rarely available on NHS**. The main route is through private physicians.



## Bureaucratic hurdle

In order to prescribe medical cannabis, the private physician needs access to a **patient's NHS records**. This requires coordination between clinics and can take **weeks or months**.



## Lack of physician support

Most physicians are **not comfortable** with prescribing cannabis due to the **complexity and lack of support** from the NHS.

The result: While the UK medical cannabis sector is fully regulated, patients are choosing other solutions.

UK Medical Cannabis Market:

**300% CAGR**

Fast growing medical cannabis market

**~£200 a month**

The average expense for a cannabis patient

**>80% retention**

Patients are committed to cannabis



# GP's telehealth service in the UK

A proven solution with an excellent Trustpilot Rating that is fully regulated by the Care Quality Commission with an approved green rating"



One of the first provider to have access to **Patients' NHS Summary Care Records** for private consultations.  
Strengthen confidence with healthcare professionals



To become one of the **First Digitally Led provider for Cannabis & General Health** in Europe, leveraging existing: Digital Technology, Physicians and Patient Community.



Agreements and Electronic Prescriptions connected to over **4000 pharmacies** including: Boots, Superdrug and CO-OP



# Creating one of Europe's largest public cannabis companies



**Asset base with multiple potential revenue streams**



**Immediate entry into Europe's biggest medical cannabis market**



**Significant access to the UK Cannabis market**



**One of the first in Europe to embrace both Cannabis and Telehealth**

---

Downstream assets & high-margin activities encompassing **delivery methods, regulatory know-how, production and distribution**

---

Established German distribution network supported by national sales team and **strong pharmacy relationships**

---

Combining the Telehealth and CBD e-marketplace for access to meaningful, growing customer base

---

Scalable model for the growing private healthcare market, driven by **Europe's adoption of virtual care services**

**KANABO<sup>+</sup>**

\* Subject to completion- Materia deal is in negotiation stage

# Summary

- Focused on two of the **fastest growing segments** of the cannabis industry today.
- **High barrier-to-entry:** the medical device is a major competitive advantage in addition to an NHS approved telehealth platform.
- **Recurring revenue model** enables greater sales certainty and retained market share.
- Supply chain built around **highest-margin activities and already fully licensed**.
- Pan-European **distribution and sales network** for both medical and wellness markets in place and **expected to generate significant sales** in the upcoming year.
- **Management team** with years of experience in both cannabis and pharma industries, including scaling start ups.

\* Subject to completion- Materia deal is in negotiation stage

**KANABO<sup>+</sup>**





# Contact Us

---

---

**KANABO<sup>+</sup>**

**Avihu Tamir**

CEO

E: [avihu@kanabogroup.com](mailto:avihu@kanabogroup.com)

---



Investor Relations

**Katrina Perez**

Partner

T: : +44 (0) 7881 622 830

[kperez@voxmarkets.co.uk](mailto:kperez@voxmarkets.co.uk)

---



Corporate Broker

**Lucy Williams**

Managing Director

T: +44 (0) 20 74690936

E: [lw@peterhousecap.com](mailto:lw@peterhousecap.com)

---

Corporate Finance

**Eran Zucker**

Managing Director

T: +44 (0) 20 7469 0932

E: [ez@peterhousecap.com](mailto:ez@peterhousecap.com)

---